These regulations are pursuant to 18 V.S.A. §§ 102 and 1001 and 3 V.S.A. § 3003, 20 V.S.A. § 3801, and 13 V.S.A. § 3504(h).
The purpose of these regulations is to protect public health through the control of communicable and dangerous diseases. These regulations require the early and prompt reporting of listed diseases so that the Department of Health may take any necessary protective action.
Table 1: Diseases, Syndromes, and Treatments Required to be Reported | |
Diseases, Syndromes, and Treatments | Reportable Laboratory Findings |
Anaplasmosis | Anaplasma phagocytophilum |
Animal bites are reportable to Town Health Officers only per Section 12.0 of this rule. Reporting form available at HS_ID_TownHealthOfficerAnimalBiteReportForm.pdf | N/A |
(healthvermont.gov). | |
Anthrax* | Bacillus anthracis* |
Babesiosis | Babesia microti, Babesia divergens, Babesia duncani |
Blastomycosis | Blastomyces species |
Blood lead levels | All results, including undetectable |
Botulism* | Clostridium botulinum* |
Brucellosis* | Brucella species* |
Campylobacteriosis | Campylobacter species |
Candida auris illness | Candida auris |
Carbapenem-resistant Acinetobacter baumannii (CRAB) infection/colonization | Carbapenem-resistant Acinetobacter baumannii (CRAB), including susceptibility results |
Carbapenem-resistant Enterobacterales (CRE) infection/colonization | Carbapenem-resistant Enterobacterales (CRE), including susceptibility results |
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection/colonization | Carbapenem-resistant Pseudomonas aeruginosa (CRPA), including susceptibility results |
Chikungunya virus disease | Chikungunya virus |
Chlamydia trachomatis infection | Chlamydia trachomatis |
Cholera* | Vibrio cholerae serogroups O1 or O139* |
COVID-19 | SARS-CoV-2 |
COVID-19-related pediatric deaths | SARS-CoV-2 |
Creutzfeldt-Jakob disease/transmissible spongiform encephalopathies | N/A |
Cryptosporidiosis | Cryptosporidium species |
Cyclosporiasis | Cyclospora cayetanensis |
Dengue | Dengue virus |
Diphtheria* | Corynebacterium diphtheriae* |
Eastern equine encephalitis | Eastern equine encephalitis virus |
Ehrlichiosis | Ehrlichia chaffeensis, Ehrlichia ewingii, Ehrlichia muris eauclairensis |
Encephalitis | N/A |
Glanders* | Burkholderia mallei* |
Gonorrhea | Neisseria gonorrhoeae |
Haemophilus influenzae disease, invasive* | Haemophilus influenzae, isolated from a normally sterile site, including susceptibility results* |
Hantavirus disease | Hantaviruses |
Hard tick relapsing fever | Borrelia miyamotoi |
Hemolytic uremic syndrome (HUS) | N/A |
Hepatitis A (acute)* | Hepatitis A virus (anti-HAV IgM)* |
Hepatitis B | Hepatitis B virus (HBsAg, anti- HBcIgM, HBeAg, HBV DNA) |
Hepatitis B, positive surface antigen in a pregnant person | Hepatitis B virus (HbsAg) |
Hepatitis C | Positive hepatitis C antibody results and all positive and non-detectable nucleic acid test results, including genotype |
Hepatitis E | Hepatitis E virus (IgM anti-HEV) |
Human immunodeficiency virus (HIV) infection/AIDS | Human immunodeficiency virus (HIV) including the following: [] HIV viral load measurement (including non- detectable results) [] All HIV subtype and HIV nucleotide sequence data from antiretroviral drug resistance testing |
Infant botulism* | Clostridium botulinum* |
Influenza: Report -Individual cases of influenza only if due to a novel strain of Influenza A* - Pediatric influenza-related deaths - Institutional outbreaks | N/A (except for novel influenza A) |
Jamestown Canyon virus disease | Jamestown Canyon virus |
La Crosse virus disease | La Crosse virus |
Legionellosis | Legionella species |
Leptospirosis | Leptospira species |
Listeriosis | Listeria monocytogenes |
Lyme disease | Borrelia burgdorferi, Borrelia mayonii |
Malaria | Plasmodium species |
Measles (Rubeola)* | Measles virus* |
Melioidosis* | Burkholderia pseudomallei* |
Meningitis, bacterial* | Neisseria meningitidis isolated from a normally sterile site*, including susceptibility results, Streptococcus pneumoniae isolated from a normally sterile site, including susceptibility results, Haemophilus influenzae isolated from a normally sterile site, including susceptibility results |
Meningococcal disease* | Neisseria meningitidis, isolated from a normally sterile site, including susceptibility results * |
Middle East Respiratory Syndrome (MERS)* | MERS CoV* |
Mpox (human monkeypox) | MPXV Clade I and Clade II, non- variola Orthopoxvirus |
Multisystem inflammatory syndrome in children (MIS- C) | SARS-CoV-2 |
Mumps | Mumps virus |
Pertussis (whooping cough) | Bordetella pertussis |
Plague* | Yersinia pestis* |
Poliovirus infection, including poliomyelitis* | Poliovirus* |
Powassan virus disease | Powassan virus |
Psittacosis | Chlamydia psittaci |
Q fever | Coxiella burnetii |
Rabies, human* and animal* cases | Rabies virus* |
Rabies postexposure prophylaxis in humans Reporting form available at HS_ID_RabiesPostexposureProphylaxisReportForm.pdf | N/A |
(healthvermont.gov). | |
Reye syndrome | N/A |
Ricin toxicity | Ricin toxin |
Rubella (German measles)* | Rubella virus |
Rubella, congenital rubella syndrome | Rubella virus |
Salmonella Paratyphi infection* | Salmonella enterica serotypes Paratyphi A, B $(tartrate negative$), and C $(S. Paratyphi$)* |
Salmonella Typhi infection* | Salmonella enterica serotype Typhi* |
Salmonellosis | Salmonella species (non-Typhi) |
Severe Acute Respiratory Syndrome (SARS)* | SARS-CoV/SARS-associated virus* |
Shiga toxin-producing E.coli (STEC) | Shiga toxin-producing E.coli (STEC) (including O157:H7) |
Shigellosis | Shigella species |
Smallpox* | Variola virus* |
Spotted fever group rickettsioses | Rickettsia species |
St. Louis encephalitis | St. Louis encephalitis virus |
Streptococcal disease, group A, invasive | Streptococcus pyogenes (group A), isolated from a normally sterile site |
Streptococcal disease, group B invasive (infants less than one month of age) | Streptococcus agalactiae (group B), isolated from a normally sterile site (infants less than one month of age) |
Streptococcus pneumoniae disease, invasive | Streptococcus pneumoniae, isolated from a normally sterile site, including susceptibility results |
Syphilis | Treponema pallidum and all confirmatory tests for syphilis that result from an initial positive screening test, regardless of result (positive and negative) |
Tetanus | Clostridium tetani |
Toxic shock syndrome | N/A |
Trichinellosis | Trichinella species |
Tuberculosis disease* | Mycobacterium tuberculosis complex, including susceptibility results, interferon gamma release assay (IGRA), tuberculin skin test (TST) |
Tuberculosis infection, latent | Interferon gamma release assay (IGRA), tuberculin skin test (TST) |
Tularemia* | Francisella tularensis* |
Vaccinia (disease or adverse event) | Vaccinia virus |
Varicella (chickenpox only) | Varicella virus |
Vibriosis | Vibrio species |
VRSA, VISA infection | Staphylococcus aureus, vancomycin resistant (VRSA) and vancomycin intermediate (VISA), including susceptibility results |
West Nile virus illness | West Nile virus |
Yellow fever | Yellow fever virus |
Yersiniosis | Yersinia enterocolitica |
Zika virus disease and infection | Zika virus |
Table 2: Laboratory Findings Required to be Reported | |
Reportable Laboratory Findings | Diseases, Syndromes, Treatments |
Anaplasma phagocytophilum | Anaplasmosis |
Babesia microti, Babesia divergens, Babesia duncani | Babesiosis |
Bacillus anthracis* | Anthrax* |
Blastomyces species | Blastomycosis |
Blood lead levels (all results, including undetectable) | N/A |
Bordetella pertussis | Pertussis (whooping cough) |
Borrelia burgdorferi | Lyme disease |
Borrelia mayonii | Lyme disease |
Borrelia miyamotoi | Hard tick relapsing fever |
Brucella species* | Brucellosis* |
Burkholderia mallei* | Glanders* |
Burkholderia pseudomallei* | Melioidosis* |
Campylobacter species | Campylobacteriosis |
Candida auris | Candida auris illness |
Carbapenem-resistant Acinetobacter baumannii (CRAB), including susceptibility results | Carbapenem-resistant Acinetobacter baumannii (CRAB) infection/colonization |
Carbapenem-resistant Enterobacterales (CRE), including susceptibility results | Carbapenem-resistant Enterobacterales (CRE) infection/colonization |
Carbapenem-resistant Pseudomonas aeruginosa (CRPA), including susceptibility results | Carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection/colonization |
CD4+ T-lymphocyte counts and percentages (all results) | N/A |
Chikungunya virus | Chikungunya virus disease |
Chlamydia psittaci | Psittacosis |
Chlamydia trachomatis | Chlamydia trachomatis infection |
Clostridium botulinum* | Botulism* and infant botulism* |
Clostridium tetani | Tetanus |
Corynebacterium diphtheriae* | Diphtheria* |
Coxiella burnetii | Q fever |
Cryptosporidium species | Cryptosporidiosis |
CSF findings (all positive results) | N/A |
Cyclospora cayetanensis | Cyclosporiasis |
Dengue virus | Dengue |
Eastern equine encephalitis virus | Eastern equine encephalitis |
Ehrlichia chaffeensis, Ehrlichia ewingii, Ehrlichia muris eauclairensis | Ehrlichiosis |
Francisella tularensis* | Tularemia* |
Haemophilus influenzae, isolated from a normally sterile site*, including susceptibility results | Invasive Haemophilus influenzae disease*, bacterial meningitis |
Hantaviruses | Hantavirus disease |
Hepatitis A virus (anti-HAV IgM)* | Acute hepatitis A* |
Hepatitis B virus (HBsAg, anti-HBc IgM, HBeAg, HBV DNA) | Hepatitis B (acute and chronic) |
Hepatitis C virus (positive antibody results and all positive and non-detectable nucleic acid test results, including genotype) | Hepatitis C (acute and chronic) |
Hepatitis E virus (IgM anti-HEV) | Hepatitis E |
Human immunodeficiency virus (HIV) including the following: [] HIV viral load measurement (including non-detectable results) [] All HIV subtype and HIV nucleotide sequence data from antiretroviral drug resistance testing | HIV/AIDS |
Interferon gamma release assay (IGRA) | Tuberculosis infection |
Jamestown Canyon virus | Jamestown Canyon virus disease |
La Crosse virus | La Crosse virus disease |
Legionella species | Legionellosis |
Leptospira species | Leptospirosis |
Listeria monocytogenes | Listeriosis |
Measles virus* | Measles (Rubeola)* |
MERS CoV* | Middle East Respiratory Syndrome (MERS)* |
MPXV Clade I and Clade II, non-variola Orthopoxvirus | Mpox (human monkeypox) |
Mumps virus | Mumps |
Mycobacterium tuberculosis complex, including susceptibility results | Tuberculosis (TB) disease*, latent TB infection |
Neisseria gonorrhoeae | Gonorrhea |
Neisseria meningitidis, isolated from a normally sterile site*, including susceptibility results | Bacterial meningitis, meningococcal disease* |
Plasmodium species | Malaria |
Poliovirus* | Poliovirus infection, including poliomyelitis* |
Powassan virus | Powassan virus disease |
Rabies virus* | Rabies, human* and animal* cases |
Ricin toxin | Ricin toxicity |
Rickettsia species | Spotted fever group rickettsioses |
Rubella virus | Rubella (German measles)*, congenital rubella syndrome |
Salmonella enterica serotype Typhi* | Salmonella Typhi infection* |
Salmonella enterica serotypes Paratyphi A, B $(tartrate negative$), and C $(S. Paratyphi$)* | Salmonella Paratyphi infection* |
Salmonella species (non-Typhi) | Salmonellosis |
SARS-CoV/SARS-associated virus* | Severe Acute Respiratory Syndrome (SARS)* |
SARS-CoV-2 | COVID-19, COVID-19-related pediatric deaths |
Shigella species | Shigellosis |
Shiga toxin-producing E.coli (STEC) (including O157:H7) | Shiga toxin-producing E.coli (STEC) |
St. Louis encephalitis virus | St. Louis encephalitis |
Staphylococcus aureus, vancomycin resistant (VRSA) and vancomycin intermediate (VISA), including susceptibility results | VRSA, VISA infection |
Streptococcus pyogenes (group A), isolated from a normally sterile site | Invasive group A streptococcal (GAS) disease |
Streptococcus agalactiae (group B), isolated from a normally sterile site (infants less than one month of age) | Neonatal invasive group B streptococcal (GBS) disease |
Streptococcus pneumoniae, isolated from a normally sterile site, including susceptibility results | Invasive Streptococcus pneumoniae disease |
Treponema pallidum and all confirmatory tests for syphilis that result from an initial positive screening test, regardless of result (positive and negative) | Syphilis |
Trichinella species | Trichinellosis |
Tuberculin skin test (TST) | Tuberculosis infection |
Vaccinia virus | Vaccinia disease or vaccine adverse event |
Varicella virus | Varicella (only chickenpox is reportable) |
Variola virus* | Smallpox* |
Vibrio cholerae serogroups O1 or O139* | Cholera* |
Vibrio species | Vibriosis |
West Nile virus | West Nile virus illness |
Yellow fever virus | Yellow fever |
Yersinia enterocolitica | Yersiniosis |
Yersinia pestis* | Plague* |
Zika virus | Zika virus disease and infection |
Pharmacists are required to report to the Department any recognized unusual or increased prescription requests, unusual types of prescriptions, or unusual trends in pharmacy visits that may result from bioterrorist acts, epidemic or pandemic disease, or novel and highly fatal infectious agents or biological toxins, and might pose a substantial risk of significant number of human fatalities or incidents of permanent or long-term disability within 24 hours of when they become aware of such an event.
Prophylaxis for conjunctivitis of the newborn (ophthalmia neonatorum) shall be administered by a health care provider to all infants immediately after birth by the medical provider attending the birth.
13-007 Code Vt. R. 13-140-007-X
December 1, 1986 Secretary of State Rule Log #86-85
AMENDED:
October 1, 1994 Secretary of State Rule Log #94-44; April 1, 1995 Secretary of State Rule Log #95-21; July 1, 1996 Secretary of State Rule Log #96-35; July 7, 1998 Secretary of State Rule Log #98-39; March 24, 2000 Secretary of State Rule Log #00-16; August 8, 2001 Secretary of State Rule Log #01-41; March 15, 2004 Secretary of State Rule Log #04-08; October 1, 2005 Secretary of State Rule Log #05-034; September 1, 2008 Secretary of State Rule Log #08-22; March 26, 2015 Secretary of State Rule Log #15-008; April 6, 2019 Secretary of State Rule Log #19-013; July 1, 2022 Secretary of State Rule Log #22-020; 8/10/2024 Secretary of State Rule Log #24-027
STATUTORY AUTHORITY:
3 V.S.A. §§ 801(b)(11), 3003(b); 13 V.S.A. § 3504; 18 V.S.A. §§ 102, 1001; 20 V.S.A. § 3801